Can-Fite BioPharma Ltd. has reached a significant milestone in its pivotal Phase III study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The company announced on November 18, 2026, that all 247 patients in the interim-analysis cohort have completed dosing. This development is crucial as it sets the stage for an upcoming interim analysis, which is expected to provide insights into the drug's efficacy and safety.

Can-Fite, a clinical-stage biotechnology company, is focused on developing proprietary small molecule drugs targeting oncological and inflammatory diseases. The completion of dosing is a pivotal step towards the interim analysis, which is anticipated to be read out by the Independent Data Monitoring Committee (IDMC) in the first quarter of 2027.

Background

Can-Fite BioPharma Ltd. operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the NYSE under the ticker CANF. Can-Fite specializes in drug development for various conditions, including psoriasis and liver diseases. Recent filings indicate ongoing activity, with multiple reports submitted in November 2026 alone.

What the Filing Says

The recent SEC filing states, "Completion of dosing marks a key milestone toward the interim analysis, which will evaluate the efficacy and safety of Piclidenoson in patients with moderate-to-severe plaque psoriasis." This statement highlights the importance of the current phase in the drug's development process.

Impact

This development may significantly affect Can-Fite's future in the pharmaceutical industry, particularly as it competes with other companies developing treatments for psoriasis and similar inflammatory conditions. The results from the interim analysis could influence investor confidence and the company's market position.

What's Next

The interim analysis results are expected to be reported in the first quarter of 2027. This upcoming analysis will be critical in determining the future trajectory of Piclidenoson and Can-Fite's overall strategy in the pharmaceutical market.